Promising opening for Giaconda
28 September, 2005 by Helen SchullerSydney-based gastrointestinal drug development company Giaconda (ASX:GIA) has listed today on the Australian Stock Exchange at AUD$0.585, eight cents above its issue price of $0.50.
Delays extend Prima-AstraZeneca partnership
27 September, 2005 by Ruth BeranAstraZeneca has agreed to extend the completion date for a validation study of Prima Biomed (ASX:PRR) subsidiary Arthron's anti-inflammatory Fc receptor target.
Narhex appoints new scientific advisory board
23 September, 2005 by Ruth BeranNarhex Life Sciences (ASX:NLS) has formed a new scientific advisory board, following Prof John Mills' appointment last week as managing director, replacing founder John Majewski, and the relocation of the company's head office to Melbourne.
Biosignal woos potential customers in oil, gas
22 September, 2005 by Helen SchullerSydney-based Biosignal (ASX:BOS) has piqued the interest of some major international oil and gas companies.
Aussie biotech getting better at global partnering: report
22 September, 2005 by Helen SchullerThe Australian biotechnology industry is showing new signs of maturity, evidenced by a substantial increase in international alliance activity, according to a new analysis by industry consultant Innovation Dynamics.
Amrad to change its name
20 September, 2005 by Ruth BeranMelbourne's Amrad Corporation (ASX:AML) will be seeking approval from shareholders to change its name.
How harmful is half-baked hiring?
16 September, 2005 by Jeremy WurmYou may be strapped for time, but a poorly-chosen new recruit could set you back even further, writes Jeremy Wurm.
Narhex board ousts MD
15 September, 2005 by Helen SchullerSydney anti-viral drug developer Narhex Life Sciences (ASX:NLS) has relocated its head office to Melbourne following the resignation of founder and managing director John Majewski.
Biosignal granted two local patents
14 September, 2005 by Helen SchullerSydney-based Biosignal (ASX:BOS) has been granted two additional Australian patents relating to its novel anti-bacterial technology.
Resonance set for US pilot study
14 September, 2005 by Helen SchullerResonance Health Group (ASX:RHT) has signed a memorandum of understanding with a US radiology service provider for a pilot study in preparation for the commercial launch of its FerriScan diagnostic test.
'Simpler' new NHMRC structure welcomed
12 September, 2005 by Graeme O'NeillAustralia's medical research community has welcomed news of major changes to the nation's sole research funding agency, the National Health and Medical Research Council (NHMRC).
Benitec speculation leads to speeding ticket
12 September, 2005 by Ruth BeranLicence discussions between RNAi specialist Benitec (ASX:BLT) and an undisclosed party caused Bentiec's share price to rise from $0.135 on September 8 to $0.17 on September 9, the company has told the ASX.
CollTech raises $2.27m in placement
12 September, 2005 by Ruth BeranWestern Australian collagen purification company CollTech (ASX:CAU) has raised $2.27 million after fees from its recent private placement and share purchase plan.
Bring back our best and brightest
12 September, 2005 by Ruth BeranThey were set up to bring key Australian scientists back from overseas. But nearly two thirds of last year's crop of Australian Research Council (ARC) Federation Fellowships was awarded to scientists already living here.
UQ researchers race to develop MRI contrast agent
08 September, 2005 by Ruth BeranScientists around the world are racing to create the first 'smart' contrast agent to enhance the use of MRI in measuring biological processes in the body, and three early-career researchers at the University of Queensland (UQ) are in the running.
